Skip to content

Comparative study on the efficacy of focused extracorporeal shock wave and nonsteroidal anti-inflammatory drugs in the treatment of hemiplegic shoulder pain

Comparative study on the efficacy of focused extracorporeal shock wave and nonsteroidal anti-inflammatory drugs in the treatment of hemiplegic shoulder pain

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099188
Enrollment
Unknown
Registered
2025-03-19
Start date
2025-03-20
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder pain after hemiplegia

Interventions

Erecoxib group:The control group received oral anti-inflammatory and analgesic treatment with ezetimibe (0.1mg twice a day for 2 weeks as one course of treatment) during the treatment period
Shock wave therapy group:The patient should sit or lie prone on the healthy side, and undergo extracorporeal shock wave therapy centered on the supraspinatus muscle, nodules, subacromial bursa, and th

Sponsors

Hengdian Wenrong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for stroke and is confirmed by CT or MRI (2) Shoulder pain and limited mobility begin to occur after hemiplegia (3) Stable condition, no cognitive impairment, suitable for follow-up (4) Age range: 30-85 years old (5) Voluntary signing of informed consent form

Exclusion criteria

Exclusion criteria: (1) Individuals with previous shoulder related diseases (2) Received shoulder joint pain treatment within one month prior to enrollment (3) Poor compliance, lack of cooperation, inability to treat and evaluate according to the course of treatment (4) Unstable vital signs, with a risk of worsening and exacerbation of the condition, making further treatment impossible

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale, VAS;

Secondary

MeasureTime frame
passive range of motion,PROM;Upper Fugl-Meyer Assessment Scale,U-FMA;

Countries

China

Contacts

Public ContactGuo Kangxiang

Hengdian Wenrong Hospital

12474644060@qq.com+86 139 6790 4746

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026